Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04952272

Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors

To study the safety and clinical effects of intratumor injecting CpG-ODN and in situ release of tumor antigen by interventional ablation or drug-eluting beads to treat advanced solid tumors.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Lung Cancer Adenocarcinoma Carcinoma Carcinoma, Hepatocellular Digestive System Diseases Digestive System Neoplasms Hepatocellular Carcinoma Liver Diseases Liver Neoplasms Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Respiratory Tract Diseases Respiratory Tract Neoplasms Solid Tumor Thoracic Neoplasms

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

About this study

  • Percutaneous microwave ablation or intratumor injection of drug-eluting beads to destroy cancer cells to release tumor-specific antigens
  • Intratumor injection of type A/C CpG-ODN with or without infusion of CAR-T cells secreting scFv against OX40
  • Assessing side effects and therapeutic efficacy after the combined treatments

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Solid advanced malignant tumors
  • Age between18 and 80 years
  • Life expectancy is greater than three months

Exclusion criteria

  • Benign tumor
  • Life expectancy is less than three months
  • Serious medical comorbidity
  • Others

Treatment and study plan

CpG-ODN

Combination Product

CAR-T cells secreting scFv against OX40

Other names: Interventional therapy technique including microwave ablation or drug-eluting beads

Primary outcomes

  1. Assessing safety and treatment efficacy on intratumor injection of CpG-ODN and in situ tumor antigen release for advanced tumors

    Time frame: up to 36 months

    Assessing incidence of side effects and primary clinical response of the intratumor injection of CpG-ODN and therpeutical in situ tumor antigen release for advanced tumors, including CR, PR, SD, and PD.

Study contacts

Contact information is provided by the study sponsor or research team.

Bingjia He, MD

CONTACT

[email protected]

+862039195965

Zhenfeng Zhang, MD, PhD

CONTACT

[email protected]

+862039195966

Sponsors and collaborators

Lead sponsor

Second Affiliated Hospital of Guangzhou Medical University

Other

Collaborators

  • Guangdong Zhaotai InVivo Biomedicine Co. Ltd.

Registry information

Official study title

Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Released by Interventional Approaches for Advanced Solid Tumors

Important dates

Study start
2021
Primary completion
2029
Study completion
2036
First posted
Jul 7, 2021
Registry last updated
Jun 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.